$SLS Merck has two combo's running now with GPS, one of them is fully paid for by MSK, they though are paying for the other with a CSPT and therefor have access to all of the data in a real time mode...
$SLS If a competitor of Gilead, say Merck for example, wanted to fast track their late stage cancer/oncology prospects then buying SLS for GPS/NPS makes sense. IMMU just bought out for $21B for their drug. That would be $2100/share here. At one-tenth of that buyout price of $2.1B it is still a solid $210/share. This company is at least $2B in value IMO
View original message